Journal Article
. 2006 Oct;103(2).
doi: 10.1007/s10549-006-9366-x.

Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue

Lida Mina 1 Sharon E Soule  Sunil Badve  Fredrick L Baehner  Joffre Baker  Maureen Cronin  Drew Watson  Mei-Lan Liu  George W Sledge  Steve Shak  Kathy D Miller  
Affiliations
  • PMID: 17039265
  •     19 citations

Abstract

Purpose: Primary chemotherapy provides an ideal opportunity to correlate gene expression with response to treatment. We used paraffin-embedded core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy.

Patients And Methods: Patients with newly diagnosed stage II or III breast cancer were treated with sequential doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6; treatment order was randomly assigned. Pretreatment core biopsy samples were interrogated for genes that might correlate with pathologic complete response (pCR). In addition to the individual genes, the correlation of the Oncotype DX Recurrence Score with pCR was examined.

Results: Of 70 patients enrolled in the parent trial, core biopsies samples with sufficient RNA for gene analyses were available from 45 patients; 9 (20%) had inflammatory breast cancer (IBC). Six (14%) patients achieved a pCR. Twenty-two of the 274 candidate genes assessed correlated with pCR (p < 0.05). Genes correlating with pCR could be grouped into three large clusters: angiogenesis-related genes, proliferation related genes, and invasion-related genes. Expression of estrogen receptor (ER)-related genes and Recurrence Score did not correlate with pCR. In an exploratory analysis we compared gene expression in IBC to non-inflammatory breast cancer; twenty-four (9%) of the genes were differentially expressed (p < 0.05), 5 were upregulated and 19 were downregulated in IBC.

Conclusion: Gene expression analysis on core biopsy samples is feasible and identifies candidate genes that correlate with pCR to primary chemotherapy. Gene expression in IBC differs significantly from noninflammatory breast cancer.

Can dynamic contrast-enhanced MRI (DCE-MRI) predict tumor recurrence and lymph node status in patients with breast cancer?
S Bahri, J-H Chen, +3 authors, M-Y Su.
Ann Oncol, 2008 Mar 08; 19(4). PMID: 18325916    Free PMC article.
Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Jan Franko, Alyssa M Krasinskas, +6 authors, A James Moser.
J Gastrointest Surg, 2008 Aug 05; 12(10). PMID: 18677542
Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
Genet Med, 2009 Jan 07; 11(1). PMID: 19125125    Free PMC article.
Genomic predictors of outcome and treatment response in breast cancer.
Lara Dunn, Angela Demichele.
Mol Diagn Ther, 2009 Jun 23; 13(2). PMID: 19537843
Review.
Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.
Ling Yao, Yan Zhang, +2 authors, Lisa X Xu.
PLoS One, 2011 Sep 21; 6(9). PMID: 21931812    Free PMC article.
Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?
Donna H Odierna, Aimee Afable-Munsuz, +5 authors, Ninez A Ponce.
Per Med, 2011 Dec 23; 8(6). PMID: 22190978    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
Barriers to the use of personalized medicine in breast cancer.
Christine B Weldon, Julia R Trosman, +2 authors, Julian C Schink.
J Oncol Pract, 2012 Nov 28; 8(4). PMID: 23180995    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.
Trine Tramm, Guido Hennig, +5 authors, Jens Overgaard.
Virchows Arch, 2013 Oct 09; 463(6). PMID: 24100522
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Irene Moy, Zhihong Lin, +3 authors, Serdar E Bulun.
PLoS One, 2013 Nov 14; 8(11). PMID: 24223121    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Patients' perceptions of gene expression profiling in breast cancer treatment decisions.
Y Bombard, L Rozmovits, +3 authors, D A Marshall.
Curr Oncol, 2014 Apr 26; 21(2). PMID: 24764705    Free PMC article.
Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.
Y Bombard, L Rozmovits, +3 authors, D A Marshall.
Curr Oncol, 2014 Jun 19; 21(3). PMID: 24940102    Free PMC article.
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Edith A Perez, Frederick L Baehner, +11 authors, Karla V Ballman.
Breast Cancer Res, 2015 Oct 03; 17(1). PMID: 26429296    Free PMC article.
How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
Deborah A Marshall, Ken Deal, +3 authors, Maureen Trudeau.
BMJ Open, 2016 Jun 04; 6(6). PMID: 27256091    Free PMC article.
Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Jon Whitney, German Corredor, +6 authors, Anant Madabhushi.
BMC Cancer, 2018 Jun 01; 18(1). PMID: 29848291    Free PMC article.
Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR.
Verena Schildgen, Mathias Warm, Michael Brockmann, Oliver Schildgen.
Sci Rep, 2020 Jan 01; 9(1). PMID: 31889145    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.